Printed From BioPortfolio.com
Array BioPharma and Pfizer Collaborate on Novel Anti-Cancer Combinations
10:25 EST 20 Dec 2017 | Speciality Pharma Journal
BOULDER, Colo., Dec. 19, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations, including Array’s MEK inhibitor, binimetinib, with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab*, a human anti-PD-L1 IgG1 monoclonal antibody. …
Original Article: Array BioPharma and Pfizer Collaborate on Novel Anti-Cancer Combinations
